GCP
WST icon

Gill Capital Partners’s West Pharmaceutical WST Stock Holding History

Gill Capital Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.76K Buy
+15
New +$3.73K ﹤0.01% 515

Other funds holding WST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Gill Capital Partners's WST Position: Q1 2026 in Review

Gill Capital Partners opened a new position in West Pharmaceutical (WST) in Q1 2026: 15 shares worth $3.76K. The stake represents ﹤0.01% of the portfolio and ranks #515 among its holdings.

753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Gill Capital Partners held 15 shares of West Pharmaceutical worth $3.76K as of Q1 2026.
  • West Pharmaceutical was a new Gill Capital Partners position in Q1 2026.
  • West Pharmaceutical made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #515 holding.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.